Access to Innovative Treatments Act of 2026

The Access to Innovative Treatments Act of 2026 changes how Medicare reviews decisions to deny or limit coverage for new drugs and biological products. It requires the Medicare administrator to start a review within 90 days of a request, includes a 30-day period for public comments, and mandates a final decision within 120 days that must address those comments. The bill also prevents Medicare from applying old coverage rules to newly approved or licensed drugs if those rules would contradict the current approval. Additionally, it stops prescription drug plans from using outdated coverage decisions to deny payment for new medications. These changes directly affect Medicare beneficiaries, drug manufacturers, and the Medicare program administrators.